Millie
your market intelligence analyst
Search Results
Edit Save
155 results
Lympho Bob 10/17/2019 11:02
The Journal of Clinical Oncology just published an article that looked at . On the surface, the results don't look all that great. But the researchers' conclusion is very clear: Cancer patients should get a flu shot . The timing of the publication is great, because this is the time when cases of the flu start to ramp up. (I just saw an article yesterday that the first flu case in my sate was reported a couple of days ago.) The study looked at 26,463 cancer patients in Ontario, Canada, between 2010-2011 and 2015-2016 (the flu season overs fall into early spring, so one season takes place over parts of two years). They used records of patients who who were tested for having the flu, and checked those against records of patients who had been d.
Lympho Bob 10/13/2019 16:47
The British Journal of Haematology has that shows that subcutaneous Rituxan (and injection) is just as safe as the intravenous method. Many of us have had Rituxan (or MabThera as it is known in some parts of the world) through intravenous administration. That was my experience -- six hours in a chair, the Rituxan very slowly dripping into a vein. The slow rate was necessary, since it is common for patients to have an allergic reaction, especially to the first round. The slow drip helps to control the reaction. I did have a reaction to the first round, and my five later rounds were a little quicker -- but not all that quick (4-5 hours). Subcutaneous Rituxan, given a shot under the skin, has been . for a couple of years now, and even longer i.
Lympho Bob 10/09/2019 19:00
There's a CAR-T resource that I came across in the last week or so. Many thanks to William, a frequent commenter, who helps run the blog, and whose wife was an early CAR-T patient. It's a TED Talk by one of the researchers who pioneered the research that led to the development of CAR-T, Dr. Carl June. It's called "" It was filmed last November. (And let me say straight away that I really appreciate his saying "could change the way." There's so much hype around many treatments, including CAR-T, that I like that he's humble enough to say it could change things, but that doesn't mean it definitely will.) Dr. June really tells a story about immunotherapy -- the idea that the body's immune system can be used to fight cancer. And, of course, that.
Lympho Bob 10/04/2019 09:31
There's a new movie out called "." It's a documentary about Dr. James Allison, a cancer research whose work on immunotherapy won him a . Last week, he did , a writer who was diagnosed with terminal melanoma until she received the treatment that was developed through the work that won Dr, Allison his Nobel Prize, a combination of Ipilimumab (an antibody, like Rituxan, but this one works on something called Cytotoxic T-lymphocyte–Associated Antigen 4, or CTLA-4] and Nivolumab (another antibody that works against Programmed Death 1, or PD-1, receptors). Without getting into too much detail, the combo works, like all immunotherpay, but making the immune system seek out cancer cells, when it would normally ignore them. The "Breakthrough" movie i.
Lympho Bob 10/01/2019 11:16
The podcast series has a new podcast on Follicular Lymphoma. Blooducation is a British organization that produces educational podcasts on lots of topics related to haematology (blood-related diseases of all kinds). Their latest is called "," and features an interview with Dr. Toby Eyre from Oxford University Hospitals. The podcast (like all Blooducation podcasts) is meant for health professionals, so it can get a little technical in spots. Still, like most of these "updates" posts, I find them interesting because they give a good "state of the art" about Folicullar Lymphoma -- the latest treatments, some of the controversies, and just generally the opinions of a well-known expert. This one is especially interesting to me because it's coming.
Lympho Bob 09/27/2019 09:17
The FDA has given . Let's break that all down. Abexinostat is an HDAC Inhibitor. Like all inhibitors, it works on cancer cells by stopping (or inhibiting) some process that's necessary for the cancer cell to grow and survive. In this case, it inhibits HDAC, or Histone Deacatylase enzymes. These enzmyes are important for cell growth because they help arrange which parts of the cell control its growth. One of HDAC's jobs is to control the genes that allow cells to keep growing. By inhibiting HDAC, Abexinostat can help control cells that are otherwise out of control (and become cancer cells). There are other HDAC inhibitors being tested, but Abexinostat is different because it is given more frequently than others, and so can work on cancer cel.
Lympho Bob 09/21/2019 07:41
The organization is looking for cancer heroes. They are asking for nominees for their cancer survivors event: "Do you have a friend or family member who has had or is still having an inspirational journey? What would you like people to know about this person’s story and the courage (s)he has shown in the face of a cancer diagnosis? How does that person inspire you?" Nominations are due October 14. The . Nominees will be recognized at an event on November 21. Now, I get the sense that this is mostly a local or regional thing. I don't imagine too many people will be traveling too far if they have been nominated. However, the nomination form starts with " Anyone is eligible " (and they are the ones who underlined it), so I think it's worth it
Lympho Bob 09/17/2019 12:41
The website OncLive has another of its excellent video series. For these series, they ask a panel of experts to talk about the most recent developments in FL. This series is called "" and it features Dr. Ian Flinn from the Sarah Cannon Research Institute in Nashville, Dr. Matthew Lunning from the University of Nebraska Medical Center, Dr. John Pagel from the Swedish Cancer Institute in Seattle, Washington, and Dr. Pier Luigi Zinzani from the University of Bologna in Bologna, Italy. An excellent lineup. The series is made up of 14 videos, each about 5 minutes long (give or take a minute or so). That's a lot of time, but it's worth it. They definitely get into the topic, and give a lot of good, up-to-date information about Follicular Lymphoma.
Lympho Bob 09/13/2019 10:30
I often post something on World Lymphoma Awareness Day, which is always September 15. I thought this year I'd get an early start. This will give you a little extra time to decide what you're going to do to raise awareness. (You're welcome.) I wrote that came out today. I'd been thinking about my own strange relationship with "Lymphoma Awareness." I mean, I'm pretty aware of lymphoma. I read and write about it every day. Kind of hard not to be aware, right? Lymphoma Awareness days and months are really for people without lymphoma. It's our chance to help them understand how common lymphoma is, and maybe inspire them to become more active in advocating for more money for cancer research. Or maybe in helping to get them to "" and look for sign.
Lympho Bob 09/08/2019 10:37
The Journal of Clinical Oncology just published "." It has potentially important implication for some Follicular Lymphoma patients. Some background first: About 20% of Follicular Lymphoma patients are grouped as "POD24" (also known as EFS24, and by a couple of other names). "POD" stands for "Progression of Disease," and POD24 is short for patients who have had their disease progress within 24 months after receiving Immunochemotherapy (like R-CHOP or R-Bendmustine). EFS24, Event-Free Survival, is a very similar concept to POD, so the group of patients goes by that name, too. (Patients who have had other treatments, like straight Rituxan, and who progress within 24 months, aren't part of this group. Anything related to POD24 or EFS24 doesn't
Lympho Bob 09/03/2019 15:27
My wife and I are now "empty nesters." Our three kids are all moved out -- even if it's temporary. My oldest is 22 now. He's been in and out of the house for a few years, sometimes living at home, sometimes living on his own, depending on circumstances. We love to have him home, but he's on his own right now. My middle kid is 20. We dropped him off at college about 10 days ago. He's a few hours away, but happy, and doing well. And my youngest is 18. We dropped her off at college a few days ago. She seems happy, too. That makes us happy. When I was diagnosed, they were 10, 8, and 6. It seems so long ago. There were times, especially early on, when I wasn't sure I'd see all of them out on there own, in college, being all grown up. I've receiv.
Lympho Bob 08/30/2019 09:17
The NCCN recently published an updated . It's written for patients, and it's worth a look, especially if you're new to all of this. The NCCN is the National Comprehensive Cancer Network. It's made up of a bunch of cancer research hospitals. Every year, they publish a different guide for oncologists for how to treat various types of cancer. So, for FL, it will break down what to do if a patient is at a certain stage and grade, and is showing certain symptoms. And if things change, or they had treatment and didn't respond, it will give advice on what to do next. It's based on the most up-to-date research, and for an oncologist who isn't a specialist, it can be very helpful, since they're trying to keep up on research for how to treat a whole
Lympho Bob 08/26/2019 13:53
When you see two articles, on the same topic, in the same day, it must be a sign that you need to think and write about that topic. Right? This morning, Blood-Cancer.com re-ran an old article by a blood cancer patient named Daniel Malito called "." I write for Blood-Cancer.com about once a month, and I read pretty much everything they publish. I especially like Daniel's work. He's funny and honest. In this piece, Daniel writes about how his body has changed, and how none of his clothes fit him after treatment. And, on top of everything else, now he has to spend money on new clothes. Yesterday, I saw a different piece in the new York Times called "" It's written by a cancer survivor named Susan Gubar, who also happens to be a famous literary.
Lympho Bob 08/21/2019 08:10
The latest issue of the journal Blood has some updated research on CAR-T in Follicular Lymphoma. The article is called "." The article describes results f a phase 1/phase 2 clinical trial involving 21 patients with relapsed/refractory Follicular Lymphoma (13 patients) and transformed Follicular Lymphoma (8 patients). This data comes from a involving CAR-T and a bunch of different blood cancers. Patients in the trial were first given a chemo combination -- Cyclophosphamide (the C in CHOP) and Fludarabin. This was done for lymphodepletion -- cutting down on the immune cells in the body. Then they were given the CAR-T (immune cells that had been removed from the patients and changed so they would recognize and destroy cancer cells). The result.
Lympho Bob 08/16/2019 08:13
The Fear never really goes away. I was diagnosed with Follicular Lymphoma almost 12 years ago. I haven't needed treatment in almost 10 years. But The Fear is still there. This may take a little while to explain. Bear with me. Last fall, our gas heating company tore up our street to put in new gas lines. Then they tore up our front lawn to put in new lines from the street to our house. Then they left a note saying they needed to tear up a wall in the house to connect our gas service. I didn't call the number because I didn't want my wall torn up. That was a few months ago, and last week they finally came to the house to say the work needed to be done. Yesterday, two very nice young men looked at the job and said they could do the work withou.
Lympho Bob 08/12/2019 11:46
More research on Maintenance therapy for Follicular Lymphoma. If I had to guess, I'd say there has been more research on Maintenance in the last 5 years than any other subject related to Follicular Lymphoma. That should tell you how important it is, but also how controversial it is -- if the questions about Maintenance had been settled years ago, we wouldn't have more and more research on it all the time. For those who need a reminder (or a lesson): Maintenance is the term for extending treatments after an initial successful treatment. The goal is to extend the success. So a patient might have the chemotherapy combination Bendmustine + Rituxan, and do very well with it, and then get more Rituxan every 2 months for another 2 years. Rituxan i.
Lympho Bob 08/08/2019 09:52
I a few months ago, and I'm going to link again and encourage you all to sign it, and share it with others. It's important for empowering cancer patients like us. The petition was created by the people at , a site that I link to a lot. It's a citizen's petition to the FDA, which is in charge of clinical trials. The petition is called ".". The idea behind the petition is to encourage the FDA to require that Quality of Life becomes an official part of determining whether or not a treatment should be approved, and more importantly, to have a record for doctors and patients of how a treatment affects Q of L. Right now, when a treatment is approved, the FDA basically looks at two things: first, is the treatment effective? What percentage of patie.
Lympho Bob 08/04/2019 14:58
I've been away for about a week. I don't know if any of you are from the Upper Penninsula in Michigan, or have visited there, but it's beautiful. I had kind of an unplanned internet diet -- we stayed in a pretty remote area, with very spotty access and no wireless. But it was worth it to capture some moments like this sunset near the Mackinac Bridge:. And I had some time for fun reading. I brought the book Secret Service Dogs with me. I have a family member who works for the Secret Service, and I love dogs, so it was a nice clearance rack choice for me. The problem was, it made me miss my own dog, Strudel, and it got me thinking about dogs all week. I actually used to have Strudel be a every now and then, long ago. Strudel is 12 years old no.
Lympho Bob 08/01/2019 08:15
OncLive is doing another one of their excellent video series. This one is called "." The video series features two Follicular Lymphoma experts -- Dr. Alexey Danilov of the Oregon Health & Science University and Dr. Carla Casulo of the University of Rochester Wilmot Cancer Institute. As the title says, their focus is on frontline treatments -- the first treatment that and FL patient receives. For many years, patients received some kind of chemotherapy. There are lots of other options now, including straight Rituxan, which is the treatment I had. There are some other non-chemo options, too. The videos look at some of the recent research that evaluates those options. The GALLIUM study discussed in a couple of the videos. The GALLIUM study look.
Lympho Bob 07/28/2019 10:51
Last week, the FDA approved . This one is called Ruxience (the first one, approved last November, ). A little bit of background and reminder: A biosimilar is kind of like a generic drug. It follows the same formula (in a sense) as a treatment that has already been approved, and has probably been around for a long time. The difference is that a generic drug is chemical -- once you have the chemical formula for the drug, it should be pretty easy to recreate it. that's what a "generic" is. It's usually cheaper because the company making the generic didn't have to spend millions or billions of dollars developing it. A biosimilar works the same way -- someone else already developed it, and a new company is coming in and trying to make a copy. Bu.

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications